Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21
Tweet
Share
E-mailGet Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
